Orally active NGF synthesis stimulators: Potential therapeutic agents in Alzheimer's disease

Kiyofumi Yamada, Atsumi Nitta, Takaaki Hasegawa, Kazuyuki Fuji, Masayuki Hiramatsu, Tsutomu Kameyama, Yoshiko Furukawa, Kyozo Hayashi, Toshitaka Nabeshima

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The degeneration of cholinergic neurons may be responsible for cognitive impairment in patients with Alzheimer's disease (AD). Since nerve growth factor (NGF) plays an important role in the survival and maintenance of cholinergic neurons in the central nervous system, this factor may have some beneficial effects on the cognitive impairment observed in patients with AD. However, since NGF does not cross the blood-brain barrier and is easily metabolized when administered peripherally, if can only be used when directly injected into the brain. In this review, we show that repeated oral administration of the NGF synthesis stimulators, idebenone and propentofylline, partially restored the age-associated decrease of NGF in the frontal and parietal cortices. Furthermore, this treatment attenuated the impairment of performance in the water maze, passive avoidance, and habituation tasks in rats with bilateral forebrain lesions, and in rats which had received continuous infusion of anti-NGF antibody into the septum. The behavioral improvement induced by idebenone and propentofylline was accompanied by recovery of both the reduced activity of choline acetyltransferase and the changes in [3H] QNB binding. These results suggest that the use of NGF synthesis stimulators may provide a novel therapeutic approach to cholinergic dysfunction.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
JournalBehavioural Brain Research
Volume83
Issue number1-2
DOIs
Publication statusPublished - 01-01-1997
Externally publishedYes

Fingerprint

Nerve Growth Factor
Alzheimer Disease
Cholinergic Neurons
Therapeutics
Parietal Lobe
Choline O-Acetyltransferase
Frontal Lobe
Prosencephalon
Blood-Brain Barrier
Cholinergic Agents
Oral Administration
Central Nervous System
Maintenance
Survival
Water
Antibodies
Brain

All Science Journal Classification (ASJC) codes

  • Behavioral Neuroscience

Cite this

Yamada, Kiyofumi ; Nitta, Atsumi ; Hasegawa, Takaaki ; Fuji, Kazuyuki ; Hiramatsu, Masayuki ; Kameyama, Tsutomu ; Furukawa, Yoshiko ; Hayashi, Kyozo ; Nabeshima, Toshitaka. / Orally active NGF synthesis stimulators : Potential therapeutic agents in Alzheimer's disease. In: Behavioural Brain Research. 1997 ; Vol. 83, No. 1-2. pp. 117-122.
@article{ec8292d461c44439bd4a58be06ad8151,
title = "Orally active NGF synthesis stimulators: Potential therapeutic agents in Alzheimer's disease",
abstract = "The degeneration of cholinergic neurons may be responsible for cognitive impairment in patients with Alzheimer's disease (AD). Since nerve growth factor (NGF) plays an important role in the survival and maintenance of cholinergic neurons in the central nervous system, this factor may have some beneficial effects on the cognitive impairment observed in patients with AD. However, since NGF does not cross the blood-brain barrier and is easily metabolized when administered peripherally, if can only be used when directly injected into the brain. In this review, we show that repeated oral administration of the NGF synthesis stimulators, idebenone and propentofylline, partially restored the age-associated decrease of NGF in the frontal and parietal cortices. Furthermore, this treatment attenuated the impairment of performance in the water maze, passive avoidance, and habituation tasks in rats with bilateral forebrain lesions, and in rats which had received continuous infusion of anti-NGF antibody into the septum. The behavioral improvement induced by idebenone and propentofylline was accompanied by recovery of both the reduced activity of choline acetyltransferase and the changes in [3H] QNB binding. These results suggest that the use of NGF synthesis stimulators may provide a novel therapeutic approach to cholinergic dysfunction.",
author = "Kiyofumi Yamada and Atsumi Nitta and Takaaki Hasegawa and Kazuyuki Fuji and Masayuki Hiramatsu and Tsutomu Kameyama and Yoshiko Furukawa and Kyozo Hayashi and Toshitaka Nabeshima",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0166-4328(97)86054-8",
language = "English",
volume = "83",
pages = "117--122",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "1-2",

}

Yamada, K, Nitta, A, Hasegawa, T, Fuji, K, Hiramatsu, M, Kameyama, T, Furukawa, Y, Hayashi, K & Nabeshima, T 1997, 'Orally active NGF synthesis stimulators: Potential therapeutic agents in Alzheimer's disease', Behavioural Brain Research, vol. 83, no. 1-2, pp. 117-122. https://doi.org/10.1016/S0166-4328(97)86054-8

Orally active NGF synthesis stimulators : Potential therapeutic agents in Alzheimer's disease. / Yamada, Kiyofumi; Nitta, Atsumi; Hasegawa, Takaaki; Fuji, Kazuyuki; Hiramatsu, Masayuki; Kameyama, Tsutomu; Furukawa, Yoshiko; Hayashi, Kyozo; Nabeshima, Toshitaka.

In: Behavioural Brain Research, Vol. 83, No. 1-2, 01.01.1997, p. 117-122.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Orally active NGF synthesis stimulators

T2 - Potential therapeutic agents in Alzheimer's disease

AU - Yamada, Kiyofumi

AU - Nitta, Atsumi

AU - Hasegawa, Takaaki

AU - Fuji, Kazuyuki

AU - Hiramatsu, Masayuki

AU - Kameyama, Tsutomu

AU - Furukawa, Yoshiko

AU - Hayashi, Kyozo

AU - Nabeshima, Toshitaka

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The degeneration of cholinergic neurons may be responsible for cognitive impairment in patients with Alzheimer's disease (AD). Since nerve growth factor (NGF) plays an important role in the survival and maintenance of cholinergic neurons in the central nervous system, this factor may have some beneficial effects on the cognitive impairment observed in patients with AD. However, since NGF does not cross the blood-brain barrier and is easily metabolized when administered peripherally, if can only be used when directly injected into the brain. In this review, we show that repeated oral administration of the NGF synthesis stimulators, idebenone and propentofylline, partially restored the age-associated decrease of NGF in the frontal and parietal cortices. Furthermore, this treatment attenuated the impairment of performance in the water maze, passive avoidance, and habituation tasks in rats with bilateral forebrain lesions, and in rats which had received continuous infusion of anti-NGF antibody into the septum. The behavioral improvement induced by idebenone and propentofylline was accompanied by recovery of both the reduced activity of choline acetyltransferase and the changes in [3H] QNB binding. These results suggest that the use of NGF synthesis stimulators may provide a novel therapeutic approach to cholinergic dysfunction.

AB - The degeneration of cholinergic neurons may be responsible for cognitive impairment in patients with Alzheimer's disease (AD). Since nerve growth factor (NGF) plays an important role in the survival and maintenance of cholinergic neurons in the central nervous system, this factor may have some beneficial effects on the cognitive impairment observed in patients with AD. However, since NGF does not cross the blood-brain barrier and is easily metabolized when administered peripherally, if can only be used when directly injected into the brain. In this review, we show that repeated oral administration of the NGF synthesis stimulators, idebenone and propentofylline, partially restored the age-associated decrease of NGF in the frontal and parietal cortices. Furthermore, this treatment attenuated the impairment of performance in the water maze, passive avoidance, and habituation tasks in rats with bilateral forebrain lesions, and in rats which had received continuous infusion of anti-NGF antibody into the septum. The behavioral improvement induced by idebenone and propentofylline was accompanied by recovery of both the reduced activity of choline acetyltransferase and the changes in [3H] QNB binding. These results suggest that the use of NGF synthesis stimulators may provide a novel therapeutic approach to cholinergic dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0031081164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031081164&partnerID=8YFLogxK

U2 - 10.1016/S0166-4328(97)86054-8

DO - 10.1016/S0166-4328(97)86054-8

M3 - Article

C2 - 9062669

AN - SCOPUS:0031081164

VL - 83

SP - 117

EP - 122

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 1-2

ER -